Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.42 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 8/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27192156 | 0.88 | FEN1 (0.39) | BTKNPEPPSJAK2FEN1CHEK1 | |
| SCHEMBL29326224 | 0.87 | NPEPPS (0.48) | NPEPPSFEN1ITGA4ITGB7TDP1 | |
| SCHEMBL29326355 | 0.84 | PARP1 (0.42) | BTKAURKARPS6KB1KCNMA1ITGA4 | |
| SCHEMBL29326345 | 0.84 | BTK (0.43) | BTKNPEPPSJAK2CHEK1ITGA4 | |
| SCHEMBL29326360 | 0.84 | HSD17B10 (0.45) | BTKNPEPPSJAK2AURKARPS6KB1 | |
| SCHEMBL29326236 | 0.83 | NPEPPS (0.44) | NPEPPSFEN1ITGA4ITGB7TDP1 | |
| SCHEMBL29326363 | 0.83 | TNKS2 (0.50) | NPEPPSFEN1ITGA4ITGB7TDP1 | |
| SCHEMBL29326170 | 0.82 | ERCC5 (0.42) | BTKNPEPPSJAK2FEN1AURKA | |
| SCHEMBL29326223 | 0.81 | FEN1 (0.58) | NPEPPSFEN1KCNMA1TDP1KDM4E | |
| SCHEMBL29326366 | 0.81 | KDM4E (0.47) | NPEPPSFEN1ITGA4ITGB7TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | BTK 2121/4885NPEPPS 168/4885JAK2 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.